Drug intelligence / Profile preview

CDFR0613

Development stage: Phase 3
Lead developer: CTC Bio
Modality: Small Molecules

Overview

CDFR0613 is an investigational small molecule drug developed by CTC Bio for use as a bowel cleansing agent prior to colonoscopy. It has been evaluated in phase 3 clinical trials for its safety and efficacy in comparison to other bowel preparation regimens, such as polyethylene glycol plus picosulfate (Coolprep Powder). The precise mechanism of action and active ingredients of CDFR0613 have not been publicly disclosed. Its primary therapeutic area is digestive system disorders, specifically colonic diseases related to colonoscopy preparation[1][2][3][4][7].

Brand names: CleanView-All

Beyond the preview

Go deeper on CDFR0613.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CDFR0613.

Explore the full profile